US9101711B2 - Intravascular nano-bubbling oxygenator - Google Patents

Intravascular nano-bubbling oxygenator Download PDF

Info

Publication number
US9101711B2
US9101711B2 US11/868,528 US86852807A US9101711B2 US 9101711 B2 US9101711 B2 US 9101711B2 US 86852807 A US86852807 A US 86852807A US 9101711 B2 US9101711 B2 US 9101711B2
Authority
US
United States
Prior art keywords
oxygenator
bubbling
lumen
nano
tube wall
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US11/868,528
Other versions
US20090093751A1 (en
Inventor
Chi-Wei Tao
Yang-Shan Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/868,528 priority Critical patent/US9101711B2/en
Publication of US20090093751A1 publication Critical patent/US20090093751A1/en
Priority to US14/602,260 priority patent/US20150133853A1/en
Application granted granted Critical
Publication of US9101711B2 publication Critical patent/US9101711B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1678Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes intracorporal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/32Oxygenators without membranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/04Heartbeat characteristics, e.g. ECG, blood pressure modulation
    • A61M2230/06Heartbeat rate only
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/20Blood composition characteristics
    • A61M2230/205Blood composition characteristics partial oxygen pressure (P-O2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00Measuring parameters of the user
    • A61M2230/50Temperature
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/0067Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • A61M25/007Side holes, e.g. their profiles or arrangements; Provisions to keep side holes unblocked

Definitions

  • the annual mortality rate for all lung diseases is estimated to be approximately 250,000 in the US in 2000. About 150,000 patients were related to acute, potentially reversible respiratory failure and 100,000 patients related to chronic respiratory failure due to chronic obstructive lung disease (COPD) or chronic irreversible respiratory failure due to other illness. The estimated economic burden of these diseases is in the range of 72 billion dollars per year. The rate of death related to COPD has increased by 54%, and the World Health Organization (WHO) estimated that COPD will affect 5-15% of all adults in industrialized countries and accounting for 3 million deaths worldwide in 2020, as the 5 th most prevalent disease and the 3 rd leading cause of mortality.
  • WHO World Health Organization
  • the primary purpose of this design is to replace the oxygenation function of the diseased lung with acute or chronic or ventilatory impairment. Because the exchange rate of CO.sub2 by the lungs is about 200 times more than that of oxygen, the oxygenation problem is the first and most serious clinical problem for us to face.
  • This invention is premised upon the fact that most of the clinical problems of CO.sub.2 retention can be resolved simply by the patients themselves without the mechanical ventilation to increase the minute ventilation. Therefore, the Applicants simply focus the design of this invention on the resolutions for the main problem of acute, moderate to severe hypoxemia and chronic respiratory failure with long-term hypoxemia.
  • the normal pressure to hyperbaric intravascular nano-bubbling oxygenator can replace the conventional mechanical ventilator, IVOX (intravascular oxygenator), IMO (intravenous membrane oxygenator), and/or ECMO (extracorporeal membrane oxygenator) to facilitate the oxygen demand of the patients.
  • IVOX intravascular oxygenator
  • IMO intravenous membrane oxygenator
  • ECMO extracorporeal membrane oxygenator
  • the invention relates artificial to the normal pressure to hyperbaric intravascular nano-bubbling oxygenator, and more particularly to the different design of either one lumen catheter and/or multi lumens catheters with numerous nano-porous surface to facilitate the flow of nano-sized pure oxygen bubbles to the cardiovascular system.
  • the primary purpose of the ventilation is to bring the air into and out the lungs, therefore oxygen can be added into the lungs and carbon dioxide can be removed.
  • the volume of the pulmonary capillary circulation is about 150 ml, spreading over a surface area of approximately 750 square feet. This capillary surface area surrounds 300 million air sacs called alveoli.
  • the deoxygenated venous return is oxygenated in less than one second in the pulmonary circulation due to huge capillary surface and extremely thin blood-alveolar barrier approximately one micrometer in distance. This allows the blood to be replenished with oxygen and for the excess carbon dioxide to be removed.
  • Positive-pressure mechanical ventilation is a somewhat efficient and safe means for improving gas exchange in the patients with acute respiratory failure.
  • serious adverse effects may occur with prolonged duration of intensive respiratory support or high oxygen fraction.
  • These hazardous effects including oxygen toxicity, barotraumas, altered hormone and enzyme systems, mechanical ventilation induced lung injury (VILI), disuse atrophy of skeleton muscles, and added to the morbidity and mortality rates for these patients.
  • VILI mechanical ventilation induced lung injury
  • extracorporeal membrane oxygenation constitutes a mechanism for prolonged pulmonary bypass, which has been developed and optimized over several decades but has limited clinical utility today as a state-of-the-art artificial lung.
  • the ECMO system Includes an extra-corporeal pump and membrane system that performs a gas transfer across membranes.
  • ECMO ECMO has become limited in its utility to select cases of neonatal respiratory failure, where reversibility is considered to be highly likely.
  • an object of the present invention is to provide a normal pressure to hyperbaric intravascular nano-bubbling oxygenation system comprising a catheter with single or multi-lumens, a tube wall with numerous nano-sized pores on its surface, capable of being inserted into a blood vessel to transport gas.
  • FIG. 1A , 1 B it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of one lumen type.
  • FIG. 2A , 2 B it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of multi lumens type.
  • FIG. 3 it is the flowchart to illustrate the method for oxygenation.
  • a partial porous catheter 110 comprises a tube wall 111 having a plurality of pores 112 .
  • the catheter 110 is capable of being inserted into a blood vessel.
  • the cross-section area of the catheter 110 is less than three fourths (3 ⁇ 4) of the cross-section area of the blood vessel.
  • the length of the catheter 110 in a blood vessel varies from person to person depending on patient's body size.
  • the catheter 10 comprises the biomaterial, such as, polymer, or ceramic, or metal, or composites, but other materials are also suitable.
  • the tube wall 111 is hydrophobic and able to prevent bacterial colonization and thrombogenesis.
  • the porous area portion of the tube wall 111 is five (5)% to nine-nine (99)% of the entire catheter in the blood vessel.
  • the sizes of the pores range from 0.3 nanometer to five hundred (500) micrometer.
  • the catheter 110 includes one closed end and one opening end.
  • the opening end is connected to a connector 120 .
  • the connector 120 connects the catheter 110 and the gas transporting apparatus 130 .
  • the gas transporting apparatus 130 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 120 .
  • the gas transporting apparatus 130 comprises a flow adjustor 131 with a flow sensor (not shown), a pressure adjustor 132 with a barometer (not shown), a thermo adjustor 133 with a thermometer (not shown) for these range parameters.
  • the catheter 110 includes one dosed end and one opening end.
  • the opening end is connected to a connector 120 .
  • FIGS. 2A and 2B are an embodiment of the present invention to illustrate a normal pressure to hyperbaric intravascular nano-bubbling oxygenator of multiple lumens type.
  • a partial porous catheter 210 comprises two lumens, one lumen tube wall 211 having lots of pores 212 ; the other lumen tube wall 213 with or without pores, and a separating wall 214 to separate the tube 210 into the gas lumen 215 with pores on outer tube wall and the liquid lumen 216 with or without pores on the outer tube wall.
  • Each of the gas lumen 215 and the liquid lumen 216 with a removable cap has an opening end and the gas lumen 215 connects to a connector 220 .
  • the other end of the liquid lumen 216 comprises an opening end to allow the guide wire or liquid passing through it.
  • the other end of the gas lumen 215 comprises a closed end.
  • the catheter 210 is capable of being inserted into a blood vessel.
  • the cross-section area of the catheter 210 is less than three fourths (3 ⁇ 4) of the cross-section area of the blood vessel.
  • the length of the catheter 210 in a blood vessel varies from person to person depending on patient's body size.
  • the catheter 210 comprises the biomaterial, such as, polymer, or ceramic or metal, or composites.
  • the tube wall 211 and tube wall 213 are hydrophobic and able to prevent bacterial colonization and thrombogenesis.
  • the porous area portion of the tube wall 211 ranges from five (5%) to ninety-nine (99%) of the entire tube that is inserted into a blood vessel whereas the porous area portion of tube wall 213 ranges from zero (0)% to ninety-nine (99)% of the entire tube in the blood vessel.
  • the sizes of these pores 212 range from zero point three (0.3) nanometer to five hundred (500) micrometer.
  • the connector 220 connects the gas lumen 215 of the catheter 210 and the gas transporting apparatus 230 .
  • the gas transporting apparatus 230 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 220 .
  • the gas transporting apparatus 230 comprises a flow adjustor 231 with a flow sensor (not shown), a pressure adjustor 232 with a barometer (not shown), a thermo adjustor 233 with a thermometer (not shown) for range parameters.
  • a pipe 140 connects the gas transporting apparatus 130 and a high pressure gas tank or any other container 142 with a regulator 141 .
  • the gas is oxygen.
  • the regulator 141 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator.
  • the thermo adjustor 133 warms or cools the oxygen to a proper temperature
  • the pressure adjuster 132 adjusts the pressure of the oxygen
  • the flow adjustor 131 controls the flow rate of the oxygen.
  • the oxygen passes the connector 120 to the tube 110 , and then distributes through the plurality of pores 112 into the blood.
  • the plurality of pores 112 help produce bubbles in a range of nanometer to micrometer scale for range parameters when transporting gas.
  • the control panel 150 calculates the feedback of the measurement of the blood oxygen concentration, vena cava pressure, heart rate, and temperature by one or one more detectors (not shown) and controls the gas transporting apparatus 130 for transporting gas at the specific range of temperature, pressure, and flowrate to the catheter 110 through the connector 120 .
  • a pressurized pure oxygen source is prepared.
  • the oxygen source may be tank containing pressurized pure oxygen.
  • a gas transporting apparatus including a flow adjuster, a pressure adjuster, and a thermal adjuster to control the range parameters of the gas flow, temperature, and pressure of the oxygen, is connected to a gas lumen of a porous catheter with nano to micro-meter sized pores.
  • the oxygen source is connected to the gas transporting apparatus.
  • the porous catheter is inserted into a blood vessel of a living body.
  • the gas transporting apparatus controls the distribution of the oxygen to the vascular system through the porous catheter.
  • a blood oxygen concentration, a vena caval pressure, a heart rate, and a temperature of the living body are measured to as the control signals to feedback to the computer in a panel.
  • the control signals are compared with the predetermined ranges set in the computer, and the panel sends commands to the gas transporting apparatus, and then back to the step 350 .

Abstract

An intravascular nano-bubbling oxygenator includes a catheter having a tube and a separating wall dividing the tube into a first tube wall and a second tube wall and to form a first lumen and a second lumen. The first tube wall has a hydrophobic outer surface and a plurality of nano-sized first pores extending therealong. The first lumen has a closed end and a first opening end connecting to a source of gaseous oxygen. The second lumen has a second opening end and a third opening end, wherein the first lumen is capable of transporting gaseous oxygen, and the second lumen is capable of transporting liquid from the second opening end to the third opening end.

Description

BACKGROUND OF THE PRESENT INVENTION
The annual mortality rate for all lung diseases is estimated to be approximately 250,000 in the US in 2000. About 150,000 patients were related to acute, potentially reversible respiratory failure and 100,000 patients related to chronic respiratory failure due to chronic obstructive lung disease (COPD) or chronic irreversible respiratory failure due to other illness. The estimated economic burden of these diseases is in the range of 72 billion dollars per year. The rate of death related to COPD has increased by 54%, and the World Health Organization (WHO) estimated that COPD will affect 5-15% of all adults in industrialized countries and accounting for 3 million deaths worldwide in 2020, as the 5th most prevalent disease and the 3rd leading cause of mortality.
The primary purpose of this design is to replace the oxygenation function of the diseased lung with acute or chronic or ventilatory impairment. Because the exchange rate of CO.sub2 by the lungs is about 200 times more than that of oxygen, the oxygenation problem is the first and most serious clinical problem for us to face. This invention is premised upon the fact that most of the clinical problems of CO.sub.2 retention can be resolved simply by the patients themselves without the mechanical ventilation to increase the minute ventilation. Therefore, the Applicants simply focus the design of this invention on the resolutions for the main problem of acute, moderate to severe hypoxemia and chronic respiratory failure with long-term hypoxemia. Due to the ongoing improvement of biomaterial, the possibility of applying normal pressure to hyperbaric nano-sized pure oxygen bubbles to improve oxygenation of the intracaval deoxygenated hemoglobin is attainable. In patients with acute respiratory failure, the normal pressure to hyperbaric intravascular nano-bubbling oxygenator can replace the conventional mechanical ventilator, IVOX (intravascular oxygenator), IMO (intravenous membrane oxygenator), and/or ECMO (extracorporeal membrane oxygenator) to facilitate the oxygen demand of the patients. In patients of chronic respiratory failure, a low-flow intravenous oxygenator can replace conventional oxygen therapy system, improving the power and the motivation of patient activities.
    • The invention is directed at the intravascular nano-bubbling oxygenator that utilizes an intravascular catheter with numerous nano-porous surface, in order to facilitate the binding of oxygen bubbles with the deoxygenated hemoglobin of red cells in the cardiovascular system. The inventions were designed to Improve the clinical hypoxic patients with any kinds of acute or chronic lung diseases.
1. Field of Invention
The invention relates artificial to the normal pressure to hyperbaric intravascular nano-bubbling oxygenator, and more particularly to the different design of either one lumen catheter and/or multi lumens catheters with numerous nano-porous surface to facilitate the flow of nano-sized pure oxygen bubbles to the cardiovascular system.
2. Description of Related Arts
The primary purpose of the ventilation is to bring the air into and out the lungs, therefore oxygen can be added into the lungs and carbon dioxide can be removed. The volume of the pulmonary capillary circulation is about 150 ml, spreading over a surface area of approximately 750 square feet. This capillary surface area surrounds 300 million air sacs called alveoli. The deoxygenated venous return is oxygenated in less than one second in the pulmonary circulation due to huge capillary surface and extremely thin blood-alveolar barrier approximately one micrometer in distance. This allows the blood to be replenished with oxygen and for the excess carbon dioxide to be removed.
There have been numerous efforts in the past 40 years to achieve artificial ventilation function, such as negative pressure and positive pressure mechanical ventilator, and extracorporeal membrane oxygenator (ECMO).
Positive-pressure mechanical ventilation is a somewhat efficient and safe means for improving gas exchange in the patients with acute respiratory failure. However, serious adverse effects may occur with prolonged duration of intensive respiratory support or high oxygen fraction. These hazardous effects, including oxygen toxicity, barotraumas, altered hormone and enzyme systems, mechanical ventilation induced lung injury (VILI), disuse atrophy of skeleton muscles, and added to the morbidity and mortality rates for these patients.
Another approach to artificial lung function, extracorporeal membrane oxygenation (ECMO) constitutes a mechanism for prolonged pulmonary bypass, which has been developed and optimized over several decades but has limited clinical utility today as a state-of-the-art artificial lung. The ECMO system Includes an extra-corporeal pump and membrane system that performs a gas transfer across membranes. Despite the numerous advances in the implementation of ECMO over the years, its core technology is unchanged and continues to face important limitations. The limitations of ECMO include the requirement for a large and complex blood pump and oxygenator system, the necessity for a surgical procedure for cannulation, the need for systemic anticoagulation, the labor intensive implementation, the exceeding high cost, and a high rate of complications, including bleeding and infection, protein absorption, and platelet adhesion on the surface of the oxygenator membrane. As a result of these limitations, ECMO has become limited in its utility to select cases of neonatal respiratory failure, where reversibility is considered to be highly likely.
    • One approach to artificial lung functions has been by gas sparing or diffusion of gas across the membrane surface of hollow fibers placed within the blood supply. Previous efforts have achieved some success, and have taught much to pulmonary physiologists, but gas sparing or diffusion has not yet achieved the degree of gas exchanges optimally desired. The development of the intravascular oxygenator (IVOX) presented a natural extension in the artificial lung art since it was capable of performing intracorporeal gas exchange across an array of hollow fiber membranes situated within the inferior vena cava but did not require any form of blood pump. The insertion of the IVOX effectively introduced a large amount of gas transfer surface area (up to 600 cm.sup.2) without alternation of systemic hemodynamics, unfortunately, as with ECMO, the IVOX system has numerous limitations including a moderate rate of achievable gas exchange, difficulty in device implantation, a relatively high rate of adverse events, and a significant rate of device malfunctions, including blood-to-gas leaks due to broken hollow fibers.
Clinically, there is still a long way to go for us to achieve perfect artificial oxygenation whether in acute patients or long-term care. Therefore, a serious need exists for new technology and therapeutic approaches that have the potential to provide acute, intermediate to chronic, and long-term respiratory support for patients suffering from severe pulmonary failure. There also remains a paramount need for an efficient and inexpensive technology to achieve sustained oxygen concentration in the blood, thereby bypassing the diseased lung without resorting to further damage.
SUMMARY OF THE PRESENT INVENTION
Accordingly, an object of the present invention is to provide a normal pressure to hyperbaric intravascular nano-bubbling oxygenation system comprising a catheter with single or multi-lumens, a tube wall with numerous nano-sized pores on its surface, capable of being inserted into a blood vessel to transport gas.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A, 1B, it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of one lumen type.
FIG. 2A, 2B, it is an embodiment of the present invention to illustrate the normal pressure to hyperbaric intravascular nano-bubbling oxygenator of multi lumens type.
FIG. 3, it is the flowchart to illustrate the method for oxygenation.
DETAILED DESCRIPTION OF THE FIRST EMBODIMENT
We presently contemplate that the embodiment of FIGS. 1A and 1B to be an embodiment of the present invention to illustrate a one lumen type of a normal pressure to hyperbaric intravascular nano-bubbling oxygenator. A partial porous catheter 110 comprises a tube wall 111 having a plurality of pores 112. The catheter 110 is capable of being inserted into a blood vessel. The cross-section area of the catheter 110 is less than three fourths (¾) of the cross-section area of the blood vessel. The length of the catheter 110 in a blood vessel varies from person to person depending on patient's body size. The catheter 10 comprises the biomaterial, such as, polymer, or ceramic, or metal, or composites, but other materials are also suitable. The tube wall 111 is hydrophobic and able to prevent bacterial colonization and thrombogenesis. The porous area portion of the tube wall 111 is five (5)% to nine-nine (99)% of the entire catheter in the blood vessel. The sizes of the pores range from 0.3 nanometer to five hundred (500) micrometer.
The catheter 110 includes one closed end and one opening end. The opening end is connected to a connector 120.
The connector 120 connects the catheter 110 and the gas transporting apparatus 130. The gas transporting apparatus 130 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 120. The gas transporting apparatus 130 comprises a flow adjustor 131 with a flow sensor (not shown), a pressure adjustor 132 with a barometer (not shown), a thermo adjustor 133 with a thermometer (not shown) for these range parameters.
The catheter 110 includes one dosed end and one opening end. The opening end is connected to a connector 120.
We presently contemplate that the embodiment of FIGS. 2A and 2B to be an embodiment of the present invention to illustrate a normal pressure to hyperbaric intravascular nano-bubbling oxygenator of multiple lumens type. A partial porous catheter 210 comprises two lumens, one lumen tube wall 211 having lots of pores 212; the other lumen tube wall 213 with or without pores, and a separating wall 214 to separate the tube 210 into the gas lumen 215 with pores on outer tube wall and the liquid lumen 216 with or without pores on the outer tube wall. Each of the gas lumen 215 and the liquid lumen 216 with a removable cap (not shown) has an opening end and the gas lumen 215 connects to a connector 220. The other end of the liquid lumen 216 comprises an opening end to allow the guide wire or liquid passing through it. The other end of the gas lumen 215 comprises a closed end. The catheter 210 is capable of being inserted into a blood vessel. The cross-section area of the catheter 210 is less than three fourths (¾) of the cross-section area of the blood vessel. The length of the catheter 210 in a blood vessel varies from person to person depending on patient's body size. The catheter 210 comprises the biomaterial, such as, polymer, or ceramic or metal, or composites. The tube wall 211 and tube wall 213 are hydrophobic and able to prevent bacterial colonization and thrombogenesis. The porous area portion of the tube wall 211 ranges from five (5%) to ninety-nine (99%) of the entire tube that is inserted into a blood vessel whereas the porous area portion of tube wall 213 ranges from zero (0)% to ninety-nine (99)% of the entire tube in the blood vessel. The sizes of these pores 212 range from zero point three (0.3) nanometer to five hundred (500) micrometer.
The connector 220 connects the gas lumen 215 of the catheter 210 and the gas transporting apparatus 230. The gas transporting apparatus 230 comprises a couple with or without an extended tube and a filter (not shown) for the connection with the connector 220. The gas transporting apparatus 230 comprises a flow adjustor 231 with a flow sensor (not shown), a pressure adjustor 232 with a barometer (not shown), a thermo adjustor 233 with a thermometer (not shown) for range parameters.
A pipe 140 connects the gas transporting apparatus 130 and a high pressure gas tank or any other container 142 with a regulator 141. In an embodiment, the gas is oxygen. The regulator 141 works as one of the main switches to allow the oxygen to be transported into the normal pressure to hyperbaric intravascular nano-bubbling oxygenator. The thermo adjustor 133 warms or cools the oxygen to a proper temperature, the pressure adjuster 132 adjusts the pressure of the oxygen, and the flow adjustor 131 controls the flow rate of the oxygen. The oxygen passes the connector 120 to the tube 110, and then distributes through the plurality of pores 112 into the blood. The plurality of pores 112 help produce bubbles in a range of nanometer to micrometer scale for range parameters when transporting gas.
The control panel 150 calculates the feedback of the measurement of the blood oxygen concentration, vena cava pressure, heart rate, and temperature by one or one more detectors (not shown) and controls the gas transporting apparatus 130 for transporting gas at the specific range of temperature, pressure, and flowrate to the catheter 110 through the connector 120.
Referring to FIG. 3, it is the flowchart to illustrate the method for oxygenation. At step 310, a pressurized pure oxygen source is prepared. The oxygen source may be tank containing pressurized pure oxygen. At step 320, a gas transporting apparatus, including a flow adjuster, a pressure adjuster, and a thermal adjuster to control the range parameters of the gas flow, temperature, and pressure of the oxygen, is connected to a gas lumen of a porous catheter with nano to micro-meter sized pores. At step 330, the oxygen source is connected to the gas transporting apparatus. At step 340, the porous catheter is inserted into a blood vessel of a living body. At step 350, the gas transporting apparatus controls the distribution of the oxygen to the vascular system through the porous catheter. At step 360, a blood oxygen concentration, a vena caval pressure, a heart rate, and a temperature of the living body are measured to as the control signals to feedback to the computer in a panel. At step 370, the control signals are compared with the predetermined ranges set in the computer, and the panel sends commands to the gas transporting apparatus, and then back to the step 350.
One skilled in the art will understand that the embodiment of the present invention as shown in the drawings and described above is exemplary only and not intended to be limiting.
The foregoing description of the preferred embodiment of the present invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form or to exemplary embodiments disclosed. Accordingly, the foregoing description should be regarded as illustrative rather than restrictive. Obviously, many modifications and variations will be apparent to practitioners skilled in this art. The embodiments are chosen and described in order to best explain the principles of the invention and its best mode practical application, thereby to enable persons skilled in the art to understand the invention for various embodiments and with various modifications as are suited to the particular use or implementation contemplated. It is intended that the scope of the invention be defined by the claims appended hereto and their equivalents in which all terms are meant in their broadest reasonable sense unless otherwise indicated. It should be appreciated that variations may be made in the embodiments described by persons skilled in the art without departing from the scope of the present invention as defined by the following claims. Moreover, no element and component in the present disclosure is intended to be dedicated to the public regardless of whether the element or component is explicitly recited in the following claims.

Claims (11)

What is claimed is:
1. An intravascular nano-bubbling oxygenator, comprising:
a catheter comprising a tube and a separating wall extended inside said tube to divide said tube into a first tube wall and a second tube wall and to form a first lumen within said first tube wall and said separating wall, and a second lumen within said second tube wall and said separating wall, wherein said first tube wall has a hydrophobic outer surface and comprises a plurality of nano-sized first pores extending therealong, which are provided with sizes ranging from 0.3 nanometer to 500 micrometer; wherein said first lumen comprises a closed end, and a first opening end connecting to a source of gaseous oxygen, said second lumen comprises a second opening end and a third opening end, said first lumen capable of transporting gaseous oxygen, and second lumen capable of transporting liquid from said second opening end to said third opening end; wherein said catheter is capable of being inserted into a blood vessel and has a cross-section area less than three fourths of the cross-section area of said blood vessel, wherein said first lumen is arranged for guiding said gaseous oxygen to longitudinally flow from said opening end toward said closed end in order to transversely distribute said gaseous oxygen to produce oxygen bubbles through said nano-sized pores directly inside said blood vessel.
2. The intravascular nano-bubbling oxygenator of claim 1, wherein said first tube wall, second tube wall and separating wall comprise biomaterial.
3. The intravascular nano-bubbling oxygenator of claim 1, wherein a first porous area of said first tube wall is five (5)% to ninety-nine (99)% of said first tube wall of said catheter being inserted into said blood vessel.
4. The intravascular nano-bubbling oxygenator of claim 1, wherein a second porous area of said separating wall is zero (0)% to ninety-nine (99)% of second tube wall of said catheter being inserted into said blood vessel.
5. The intravascular nano-bubbling oxygenator of claim 1, further comprising a connector provided at said first opening end of said first lumen to input gaseous oxygen to said first lumen, said connector further comprising a gas input end.
6. The intravascular nano-bubbling oxygenator of claim 5, further comprising a gas transporting apparatus connected to said gas input end of said connector.
7. The intravascular nano-bubbling oxygenator of claim 6, wherein said gas transporting apparatus comprises a flow adjustor, a pressure adjustor, and a thermo adjuster for range parameters.
8. The intravascular nano-bubbling oxygenator of claim 6, further comprising a gaseous oxygen source connected to said gas transporting apparatus.
9. The intravascular nano-bubbling oxygenator of claim 8, wherein said gaseous oxygen source comprises a pipe, a regulator, and a gas container.
10. The intravascular nano-bubbling oxygenator of claim 6, further comprising a control panel connected to said gas transporting apparatus to control the inputting of said gaseous oxygen.
11. The intravascular nano-bubbling oxygenator of claim 10, wherein said control panel controls transporting of said gaseous oxygen by a feedback of measuring a blood oxygen concentration, a vena caval pressure, a heart rate, and a temperature.
US11/868,528 2007-10-07 2007-10-07 Intravascular nano-bubbling oxygenator Active 2029-01-22 US9101711B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/868,528 US9101711B2 (en) 2007-10-07 2007-10-07 Intravascular nano-bubbling oxygenator
US14/602,260 US20150133853A1 (en) 2007-10-07 2015-01-21 Intravascular nano-bubbling oxygenator

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/868,528 US9101711B2 (en) 2007-10-07 2007-10-07 Intravascular nano-bubbling oxygenator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/602,260 Continuation US20150133853A1 (en) 2007-10-07 2015-01-21 Intravascular nano-bubbling oxygenator

Publications (2)

Publication Number Publication Date
US20090093751A1 US20090093751A1 (en) 2009-04-09
US9101711B2 true US9101711B2 (en) 2015-08-11

Family

ID=40523891

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/868,528 Active 2029-01-22 US9101711B2 (en) 2007-10-07 2007-10-07 Intravascular nano-bubbling oxygenator
US14/602,260 Abandoned US20150133853A1 (en) 2007-10-07 2015-01-21 Intravascular nano-bubbling oxygenator

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/602,260 Abandoned US20150133853A1 (en) 2007-10-07 2015-01-21 Intravascular nano-bubbling oxygenator

Country Status (1)

Country Link
US (2) US9101711B2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527075A (en) * 2014-03-17 2015-12-16 Daassist As Percutaneous system, devices and methods
US10893847B2 (en) 2015-12-30 2021-01-19 Nuheart As Transcatheter insertion system
JP6653185B2 (en) * 2016-02-23 2020-02-26 泉工医科工業株式会社 Bubble generator
CN106377811B (en) * 2016-08-29 2019-11-15 安徽通灵仿生科技有限公司 A kind of vein membrane oxygenation device and oxygen close method
CN106237414B (en) * 2016-08-29 2019-11-15 安徽通灵仿生科技有限公司 A kind of vein micro-nano mist oxygen device and oxygen therapy method
CN106215262B (en) * 2016-08-29 2018-11-20 安徽通灵仿生科技有限公司 Oxygenation device and oxygen close method in a kind of venous lumen
US10537672B2 (en) 2016-10-07 2020-01-21 Nuheart As Transcatheter device and system for the delivery of intracorporeal devices
US10335528B2 (en) 2016-10-07 2019-07-02 Nuheart As Transcatheter method and system for the delivery of intracorporeal devices
US10537670B2 (en) 2017-04-28 2020-01-21 Nuheart As Ventricular assist device and method
US10888646B2 (en) 2017-04-28 2021-01-12 Nuheart As Ventricular assist device and method
CN109621052B (en) * 2019-01-31 2021-06-22 陈晓阳 Intravascular oxygen supply system and method
US20220080106A1 (en) * 2020-09-01 2022-03-17 Agitated Solutions Inc. Intravascular oxygenation system and method

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186713A (en) 1990-11-01 1993-02-16 Baxter International Inc. Extracorporeal blood oxygenation system and method for providing hemoperfusion during transluminal balloon angioplasty procedures
US5261875A (en) * 1991-02-14 1993-11-16 Wayne State University Method and apparatus for injection of gas hydrates
US5336164A (en) 1992-01-06 1994-08-09 The Pennsylvania Research Corporation Intravascular membrane lung apparatus
US5376069A (en) 1991-03-27 1994-12-27 Hattler; Brack G. Inflatable percutaneous oxygenator with internal support
US5407426A (en) 1991-02-14 1995-04-18 Wayne State University Method and apparatus for delivering oxygen into blood
US5634892A (en) 1995-02-23 1997-06-03 Whalen; Robert L. Extracorporeal membrane oxygenator
US20020161321A1 (en) * 1994-05-27 2002-10-31 Sweezer, William P. Method of occluding a patient's ascending aorta and delivering cardioplegic fluid
US20030138350A1 (en) * 1998-05-08 2003-07-24 John Macoviak Circulatory support system and method of use for isolated segmental perfusion
US6746417B2 (en) * 1997-08-15 2004-06-08 Therox Inc Apparatus for generalized extracorporeal support
US20050245897A1 (en) * 1998-02-03 2005-11-03 Salient Interventional Systems, Inc. Intravascular device and method of manufacture and use
US20070131610A1 (en) * 2005-12-13 2007-06-14 General Electric Company Membrane-based apparatus and associated method
US20110264031A1 (en) * 2006-04-24 2011-10-27 Ekos Corporation Ultrasound therapy system

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5186713A (en) 1990-11-01 1993-02-16 Baxter International Inc. Extracorporeal blood oxygenation system and method for providing hemoperfusion during transluminal balloon angioplasty procedures
US5261875A (en) * 1991-02-14 1993-11-16 Wayne State University Method and apparatus for injection of gas hydrates
US5407426A (en) 1991-02-14 1995-04-18 Wayne State University Method and apparatus for delivering oxygen into blood
US5376069A (en) 1991-03-27 1994-12-27 Hattler; Brack G. Inflatable percutaneous oxygenator with internal support
US5336164A (en) 1992-01-06 1994-08-09 The Pennsylvania Research Corporation Intravascular membrane lung apparatus
US20020161321A1 (en) * 1994-05-27 2002-10-31 Sweezer, William P. Method of occluding a patient's ascending aorta and delivering cardioplegic fluid
US5634892A (en) 1995-02-23 1997-06-03 Whalen; Robert L. Extracorporeal membrane oxygenator
US6746417B2 (en) * 1997-08-15 2004-06-08 Therox Inc Apparatus for generalized extracorporeal support
US20050245897A1 (en) * 1998-02-03 2005-11-03 Salient Interventional Systems, Inc. Intravascular device and method of manufacture and use
US20030138350A1 (en) * 1998-05-08 2003-07-24 John Macoviak Circulatory support system and method of use for isolated segmental perfusion
US20070131610A1 (en) * 2005-12-13 2007-06-14 General Electric Company Membrane-based apparatus and associated method
US20110264031A1 (en) * 2006-04-24 2011-10-27 Ekos Corporation Ultrasound therapy system

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
A.B. Lub, Nunn's Applied Respiratory Physiology, 5th ed., 2000.
Brunet F, Permissive hypercapnia and intravascular oxygenators in the treatment of patients with ARDS. Artif Organs, Nov. 1994; vol. 18 (11), pp. 840-845.
C.S. Cox, Jr., Intracorporeal CO2 Removal and Permissive Hypercapnia to Reduce Airway Pressure in Acute Respiratory Failure.
Cattaaneo G, Compact intra- and extracorporeal oxygnator developments. Perfusion, Jul. 2004; vol. 19 (4), pp. 251-255.
Conrad SA, In vivo gas transfer performance of the intravascular oxygenator. Artif Organs, Nov. 1994; vol. 18(11), pp. 840-845.
Conrad SA, Major findings from the clinical trials of the intravascular oxygenator. Artif Organs, Nov. 18, 1994 (11), pp. 846-863.
D.R. Hess, et al., Respiratory Care: Priniciples & Practice, W.B. Saunders & Co., 2002.
Dean R. Hess, et al., Respiratory Care: Principles & Practice. 2002.
F. Brunet, J.P. Mira, C. Cerf, et al., Permissive Hypercapnia & Intravascular Oxygenator in the Treatment of Patients with ARDS, Artif Organs, Nov. 1994; 18(11):826-832.
Gentilello LM, The intravascular oxygenator (IVOX): preliminary results of a new means of performing extrapulmonary gas exchange. J Trauma, Sep. 1993; vol. 35(3), pp. 399.
Giorgio Cattaneo, Andreas Straubeta, Helmut Reul, Compact Intra- and Extracorporeal Oxygenator Developments, Perfusion 2004; 19: 251-255, Helmholtz Inst. for Biomed Eng, Germany.
Giorgio Cattaneo, Andreas Strauβ, Helmut Reul, Compact Intra- and Extracorporeal Oxygenator Developments, Perfusion 2004; 19: 251-255, Helmholtz Inst. for Biomed Eng, Germany.
H. Kawakami, Y. Mori, J. Takagi, S. Nagaoka, T. Kanamori T. Shinbo, et al., Develop. of a Novel Polyimide Hollow Fiber for Intravascular Oxygenator, Asaio J., 1997; 43:M490.
J.B. Zwischenberger & S.K. Alpard, Artificial Lungs: a New Inspiration, Perfusion 2002; 17: 253-268, Div of Cardiothoracic Surgery, Univ of Texas Medical Branch, USA.
J.B. Zwischenberger, Weike Tao, Akhil Bidani, Intravascular Membrane Oxygenator & Carbon Dioxide Removal Devices: a Review of Performance & Improvements. ASIAO J., 1999.
J.D. Mortensen, An Intravenacaval Blood Gas Exchnage (IVCBGE) Device: A Preliminary Report, Trans Am Soc Artif Intern Organs, 1987.
J.D. Mortensen, G. Berry, Conceptual and Design Features of a Practical, Clinically Effective, Intraveneous Device (IVOX), Int. J. Artif Organs, 1989, 12(6):384-389.
J.D. Mortensen, S. Talbot, J.A. Burkart, Cross-Section Internal Diameters of Human Cervical and Femoral Blood Vessels, Jan. 1990, 226(1):115-124.
J.R. Levick, An Introduction to Cardiovascular Physiology, 4th ed., 2003.
J.R. Levick, An Introduction to Cardiovascular Physiology, 4th ed., A Hodder Arnold Publication, 2003.
K. Tanishita, G. Panol, P.D. Richardson, P.M. Galletti, Gas Transport in the Intracorporeal Oxygenator with Woven Tubes, Artif Organs, Nov. 1994; 18(11):797-800.
K.M. Sim, T.W. Evans, B.F. Keogh, Clinical Strategies in Intravascular Gas Exchange, Artif Organs, Jul. 1996; 20(7):807-10. Royal Brompton Hospital, London, United Kingdom.
Kawakami H, Development of a novel polyimide hallow fiber for an intravascular oxyenagtor. ASAIO J, Sep.-Oct. 1997; vol. 43(5) pp. M490-M494.
L. Andrew, Nunn's Applied Respiratory Physiology, 5th ed., 2000.
L.M. Gentilello, et al., The Intravascular Oxygenator (IVOX). Preliminary Results of a New Means of Performing Extrapulmonary Gas Exchange, J Trauma, Sep. 1993, 35(3):399-404.
M. Tonz, L.K. Von Segesser, B. Leskosek, M.I. Turina, Quantitative Gas Transfer of an Intravascular Oxygenator, Annals of Thoracic Surgery, Jan. 1994, 57(1):146-150.
Mihaljevic T, Influence of hemodynamics on the performances of intravascular gas exchanger. Ann Thorac Surg, Dec. 1995; vol. 60(6), pp. 1665-1670.
Mortensen JD (1987) An intravenacaval blood gas exchange (IVCBGE) device: a preliminary report. Trans Am Sac Artif Int Org 33: 570-573.
Mortensen JD, Berry G (1989) Conceptual and design features of a practical, clinically effective, intravenous device (IVOX). Int J Artif Organs 12: 384-389.
Mortensen JD, Talbot S, Burkart JA (1990) Cross-section internal dismeters of human cervical and femoral blood vessels: relationship to subject's sex, age, body size. Anat.
S.A. Conrad, A. Bagley, B. Bagley, R.N. Schaap, Major Findings from the Clinical Trials of the Intravascular Oxygenator, Artif Organs Nov. 1994, 18(11):846-863, USA.
S.A. Conrad, J.B. Zwischenberger, J.M. Eggerstedt, Akhil Bidani, Artif Organs, Nov. 1994, 18(11):840-845, Louisiana State Univ Medical Center & Univ of Texas Medical Branch, US.
Sim KM, Clinical strategies in intravascular gas exchange. Jul. 1996; vol. 20(7), pp. 807-810.
T. Mihaijevic, et al., Influence of Hemodynamics on the Performances of Intravascular Gas Exchangers, Ann of Thoracic Surgery, Dec. 1995, vol. 60(6):1665-1670.
T.J. Hewitt, et al., A Mathematical Model of Gas Exchange in an Intravenous Membrane Oxygenator, Ann. of Biomed. Engineer., vol. 26, pp. 166-178, 1998.
Tanishita K., Gas transport in the intracorporeal oxygenator with woven tubes. Artif Organs. Nov. 1994; vol. 18(11), pp. 797-800.
Tao W, Improving gas exchange performance of the intravascular oxygenator by active blood mixing, ASAIO J., Jul.-Sep. 1994; vol. 40(3), pp. 527-532.
Tao W, Strategies to reduce surface area requirements for carbon dioxide removal for an intravenacaval gas exchange device. ASAIO J., Jul.-Sep. 1995; vol. 41(3), pp. M567-M572.
Tao, W., et al.. Strategies to Reduce Surface Area Requirements for Carbon Dioxide Removal for an Intravenacaval Gas Exchange Device, ASAIO J., vol. 41 (3), pp. M567-M572, 1995.
Todd J Hewitt, et al. A Mathemaical Model of Gas Exchange in an Intravenous Membrane Oxygenator, Ann. Biomed. Engineer. vol. 26, pp. 166-178, 1998.
Tonz M, Quantitative gas transfer of an intravascular oxygenator. Jan. 1994; vol. 57 (1), pp. 146-150.
W. Tao, et al., Improving Gas Exchange Performance of the Intravascular Oxygenator by Active Blood Mixing, ASIAO J., Jul.-Sep. 1994; 40(3):527-532.
Zwischenberger JB, Artificial lungs: a new inspiration. Perfusion Jul. 2002; vol. 17(4), pp. 253-268.
Zwischenberger JB, Intravascular membrane oxygenator arid carbon dioxide removal devices: a review of performance and improvements. ASAIO Journal Jan.-Feb. 1999; vol. 45(1), pp.

Also Published As

Publication number Publication date
US20150133853A1 (en) 2015-05-14
US20090093751A1 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
US9101711B2 (en) Intravascular nano-bubbling oxygenator
US7135008B2 (en) Method and apparatus for ultrafiltration utilizing a peripheral access dual lumen venous cannula
Allardet-Servent et al. Safety and efficacy of combined extracorporeal CO2 removal and renal replacement therapy in patients with acute respiratory distress syndrome and acute kidney injury: the pulmonary and renal support in acute respiratory distress syndrome study
ES2559667T3 (en) Ultrafiltration apparatus comprising a long peripheral access venous cannula for blood collection
JP4897477B2 (en) Device for automatically measuring pulmonary blood flow in a subject
JP4034726B2 (en) Vascular cannulation instrument
Quintel et al. Extracorporeal membrane oxygenation for respiratory failure
KR102318993B1 (en) Carbon dioxide removal system
WO2009026468A1 (en) Photoplethysmographic sensor based blood gas monitor device for analysis, research and calibration in an extracorporeal circuit or an extracorporeal pulse simulation system
Shenaq et al. Continuous monitoring of mixed venous oxygen saturation during aortic surgery
Samarska et al. Troubleshooting the rat model of cardiopulmonary bypass: effects of avoiding blood transfusion on long-term survival, inflammation and organ damage
US10086130B2 (en) Blood oxygenator device
Federspiel et al. Ex vivo testing of the intravenous membrane oxygenator
WO2018001177A1 (en) Medical catheter
Crystal et al. Coronary vasodilation by isoflurane: Abrupt versus gradual administration
Carr et al. Peritoneal perfusion with oxygenated perfluorocarbon augments systemic oxygenation
JP4226217B2 (en) Apparatus for preparing and transporting oxygen-enriched liquids
Tönz et al. Quantitative gas transfer of an intravascular oxygenator
US20070255159A1 (en) Independent control and regulation of blood gas, pulmonary resistance, and sedation using an intravascular membrane catheter
Hurtig et al. Reduction of hypoxic pulmonary vasoconstriction by nitrous oxide administration in the isolated perfused cat lung
Cockroft et al. Initial evaluation of an intracorporeal oxygenation device
US20230338634A1 (en) Extracorporeal oxygenation system for low flow rates and methods of use
JP2024506924A (en) Catheters and systems for injecting gas-enriched liquids directly into patients
Strudthoff et al. In-vitro and In-vivo Feasibility Study for a Mobile VV-ECMO and ECCO2R System
JP4380165B2 (en) Extracorporeal circuit and circulator for low weight patients

Legal Events

Date Code Title Description
STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, MICRO ENTITY (ORIGINAL EVENT CODE: M3551); ENTITY STATUS OF PATENT OWNER: MICROENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, MICRO ENTITY (ORIGINAL EVENT CODE: M3552); ENTITY STATUS OF PATENT OWNER: MICROENTITY

Year of fee payment: 8